Biomarker ID | 1997 |
PMID | 22589488 |
Year | 2012 |
Biomarker | Methylation status of RASGRF2 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Methylated in Clinical recurrence |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Clinical recurrence vs. biochemical recurrence |
Type of Biomarker | Prognostic |
Cohort | clinical recurrence (n = 80) versus biochemical recurrence (n = 43) |
Senstivity | Training: 66.1 (52.6–77.9); validation: 75.4 (50.9–91.3) |
Specificity | Training: 69.2 (52.4–82.9); validation:60.3 (36.0–80.8) |
AUC | Training: 0.69; validation: 0.76 |
Accuracy | NA |
Level Of Significance | <0.0015 |
Method Used | Pyrosequencing |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | RASGRF2 |